(0.04%) 5 024.26 points
(0.47%) 37 932 points
(-0.21%) 15 650 points
(0.19%) $82.85
(2.69%) $1.758
(0.38%) $2 397.40
(0.49%) $28.54
(-0.41%) $950.30
(0.22%) $0.939
(0.36%) $11.03
(0.08%) $0.803
(-0.20%) $93.88
Live Chart Being Loaded With Signals
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories...
Stats | |
---|---|
Today's Volume | 92 055.00 |
Average Volume | 1.06M |
Market Cap | 8.69B |
EPS | $0 ( 2024-02-06 ) |
Next earnings date | ( $0.440 ) 2024-04-29 |
Last Dividend | $1.087 ( 2017-01-25 ) |
Next Dividend | $0 ( N/A ) |
P/E | 25.65 |
ATR14 | $0.0420 (0.11%) |
Volume Correlation
Qiagen NV Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Qiagen NV Correlation - Currency/Commodity
Qiagen NV Financials
Annual | 2023 |
Revenue: | $1.97B |
Gross Profit: | $1.22B (62.23 %) |
EPS: | $1.540 |
Q4 | 2023 |
Revenue: | $509.16M |
Gross Profit: | $345.14M (67.79 %) |
EPS: | $0.440 |
Q3 | 2023 |
Revenue: | $475.89M |
Gross Profit: | $297.96M (62.61 %) |
EPS: | $0.350 |
Q2 | 2023 |
Revenue: | $494.86M |
Gross Profit: | $312.15M (63.08 %) |
EPS: | $0.370 |
Financial Reports:
No articles found.
Qiagen NV Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00208 | 2002-12-26 |
Last Dividend | $1.087 | 2017-01-25 |
Next Dividend | $0 | N/A |
Payout Date | 2017-01-31 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $1.089 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.39 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.37 | |
Div. Directional Score | 7.23 | -- |
Year | Amount | Yield |
---|---|---|
2002 | $0.00208 | 0.01% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0 | 0.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $1.087 | 3.71% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
ZTR | Dividend King | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
SRV | Dividend Royal | 2023-12-04 | Monthly | 18 | 7.53% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.174 | 1.500 | 6.53 | 9.79 | [0 - 0.5] |
returnOnAssetsTTM | 0.0558 | 1.200 | 8.14 | 9.77 | [0 - 0.3] |
returnOnEquityTTM | 0.0930 | 1.500 | -0.0782 | -0.117 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.990 | 0.800 | 5.05 | 4.04 | [1 - 3] |
quickRatioTTM | 1.458 | 0.800 | 6.13 | 4.90 | [0.8 - 2.5] |
cashRatioTTM | 0.619 | 1.500 | 7.67 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.82 | -8.74 | [0 - 0.6] |
interestCoverageTTM | 8.73 | 1.000 | 7.88 | 7.88 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.33 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.402 | -1.500 | 8.39 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.643 | 1.000 | 2.62 | 2.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.237 | 1.000 | 7.26 | 7.26 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.300 | 1.000 | 9.45 | 9.45 | [0.2 - 2] |
assetTurnoverTTM | 0.321 | 0.800 | -1.191 | -0.953 | [0.5 - 2] |
Total Score | 10.09 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 26.71 | 1.000 | 7.40 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0930 | 2.50 | -0.0503 | -0.117 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.340 | 2.00 | 9.55 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.20 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.08 | 2.00 | 9.31 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.475 | 1.500 | -0.167 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.234 | 1.000 | 6.66 | 0 | [0.1 - 0.5] |
Total Score | 4.37 |
Qiagen NV
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators